Addressing Treatment Challenges in Cystic Fibrosis

Slides:



Advertisements
Similar presentations
Cystic Fibrosis Pathogens Activate Ca 2+ -dependent mitogen-activated Protein Kinase Signaling Pathways in Airway Epithelial Cells by Aubrey Osborne and.
Advertisements

BY ELIZABETH LITTLE AND LEAH RAYGO Cystic Fibrosis: The Crisis in Ireland.
EudraCT number: ISRCTN number: ISRCTN Chief Investigator: Dr Simon Langton Hewer Co-Investigator: Prof Alan Smyth Trial Co-ordinator:
Cystic Fibrosis "Woe to that child which when kissed on the forehead tastes salty. He is bewitched and soon must die." This European adage accurately describes.
Update on Cystic Fibrosis – treatments and new products Dr Caroline Pao, Consultant Respiratory Paediatrician, Royal London Hospital.
New Developments in Cystic Fibrosis
Research collaboration in CF
Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;
Understanding Treatment Goals for Patients With Onychomycosis
Pseudomonas Infection in Cystic Fibrosis
Clinical Trials in IBD.
Chronic Hepatitis C Virus Infection
Demystifying Idiopathic Pulmonary Fibrosis
Pseudomonas Lung Infections in Cystic Fibrosis
Current Controversies in Multiple Sclerosis Management
The HCV Revolution: Are You and Your Practice Ready?
The Genomics of Cancer and Molecular Testing:
Stepping Up Asthma Control for Effective Management
Advances in Cystic Fibrosis 2017
Patient-Centered Care in Cystic Fibrosis
Optimizing Outcomes in the Management of GIST
SGLT2 Inhibitors in the Modern Era: Why and Where?
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients  R. Cantón, N. Cobos,
Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.
Infections in Patients with Cystic Fibrosis
HBV Care Models: Community Collaborations for Best Practices
Out With the Old and In With the New, Again?
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Advances in Cystic Fibrosis Perspectives From Orlando, 2016
The future of urate-lowering strategies for gout
Evaluating Effects of CFTR Modulation in Cystic Fibrosis
Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients  Helle Krogh Johansen, Samuel.
Advances in Cystic Fibrosis: Perspectives from Phoenix 2015
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014
D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M
Hepatitis C: After the Diagnosis
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Managing Age-Related Clinical Issues in Hemophilia
A. Oliver, A. Mena  Clinical Microbiology and Infection 
A Guideline-Based Approach to HCV Care
Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation  Shahid I. Sheikh, Frederick R. Long, Karen.
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
What Does the Future Hold and What Will It Mean for Patients?
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden  Per Kristian Knudsen, Hanne.
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Clinical Challenges and Updates in Managing Seizure Clusters
November, 2018 Ljubljana, Slovenia
When Is Intrathecal Drug Delivery Appropriate?
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment  Matthias Kappler,
Strategies for Infection Control in Cystic Fibrosis
Incorporating New PAH Treatments Into Clinical Practice
Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P
NAFLD and NASH in Europe and Canada
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Best Practices in Building HIV Care Networks
Presentation transcript:

Addressing Treatment Challenges in Cystic Fibrosis

Program Goals

Pseudomonas aeruginosa

Eradication of Mucoid Pseudomonas Infection EPIC Clinical Trial*

EPIC Results

Management of Exacerbations

Cystic Fibrosis Guidelines

Cystic Fibrosis Guidelines

Why Don’t Physicians Follow Clinical Practice Guidelines?

Personalized Medicine Targeting the CFTR

Strategies for Modifying the Underlying Defect in CF

Strategies for Modifying the Underlying Defect in CF (cont)

Ivacaftor in Patients With CF and the G551D Mutation

F508 (F508del)

Corrector Therapy Phase 2 Results of Lumacaftor + Ivacaftor

Looking to the Future

Will Improving CFTR Function Affect Chronic Pseudomonas Infection?

Practical Advice to Address the Challenges of Complex Medical Regimens

Abbreviations

References

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.